Cure My Disease

Don't miss your cure!

 Log in / Sign up

Telehealth bundle aims to cut maternal deaths in remote nepal

NCT ID NCT07717619

Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests a package of care for pregnant women at high risk of complications in rural Nepal. The bundle includes identifying high-risk pregnancies, teleconsultations with experts, weekly calls from a patient navigator, training for local health providers, and regular telehealth clinic visits. Researchers want to see if this approach is acceptable, feasible, and effective at reducing life-threatening events for mothers and newborns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a bundle of screening, teleconsultation, patient navigation, provider training, and telehealth clinic visits
What this could lead to
If successful, this approach could reduce life-threatening complications for pregnant women and newborns in rural areas with limited access to specialists.
What could go wrong
This is a small, early-stage implementation study in one health center, so results may not apply broadly. The bundle relies on mobile phone access and local infrastructure, which could limit its effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * all pregnant women above who are receiving antenatal care at Melamchi Primary Health Care Center Exclusion Criteria: * life-threatening maternal or fetal conditions requiring immediate tertiary-level care * unable to provide informed consent due to cognitive or language barriers * do not have access to a mobile phone for telehealth consultations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High risk pregnancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

High risk pregnancy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Melamchi Primary Health Care Center

    Melamchi, Bagmati, Nepal

More trials for these conditions

Other studies related to the condition(s) this trial covers.